Form 8-K - Current report:
SEC Accession No. 0001193125-25-053978
Filing Date
2025-03-13
Accepted
2025-03-13 16:40:30
Documents
22
Period of Report
2025-03-12
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d901047d8k.htm   iXBRL 8-K 31853
2 EX-1.1 d901047dex11.htm EX-1.1 227890
3 EX-5.1 d901047dex51.htm EX-5.1 7676
4 EX-99.1 d901047dex991.htm EX-99.1 9164
5 EX-99.2 d901047dex992.htm EX-99.2 9497
9 GRAPHIC g901047g0313092137012.jpg GRAPHIC 3897
10 GRAPHIC g901047g0313092351300.jpg GRAPHIC 3904
11 GRAPHIC g901047g0313100532888.jpg GRAPHIC 2977
12 GRAPHIC g901047g0313102205628.jpg GRAPHIC 6154
13 GRAPHIC g901047g0313102231161.jpg GRAPHIC 7322
  Complete submission text file 0001193125-25-053978.txt   515356

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA tars-20250312.xsd EX-101.SCH 2842
7 XBRL TAXONOMY EXTENSION LABEL LINKBASE tars-20250312_lab.xml EX-101.LAB 17995
8 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE tars-20250312_pre.xml EX-101.PRE 11256
24 EXTRACTED XBRL INSTANCE DOCUMENT d901047d8k_htm.xml XML 3647
Mailing Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618
Business Address 15440 LAGUNA CANYON ROAD IRVINE CA 92618 (949) 409-9820
Tarsus Pharmaceuticals, Inc. (Filer) CIK: 0001819790 (see all company filings)

EIN.: 814717861 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39614 | Film No.: 25736445
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)